Teva Pharmaceutical Industries (TEVA) Could Be 11% Undervalued As FDA Accepts Ecopipam Filing

Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after the U.S. Food and Drug Administration accepted its New Drug Application for ecopipam, a first in class pediatric Tourette syndrome treatment.

Despite the share price easing around 3% over the last day and 2% over the past week, Teva Pharmaceutical Industries has a 1 month share price return of about 4% and a year to date share price return of around 18%, while total shareholder return over the past year is close to 100%. This reflects how investors have reacted to the company’s recent pipeline updates, proposed neuroscience acquisitions and legal settlement activity.

Scan for other companies pursuing underappreciated growth stories in healthcare and beyond with our hand picked list of 19 high quality undiscovered gems aligned to similar themes.

After Teva Pharmaceutical Industries nearly doubled shareholders’ money over the past year, yet eased off in recent days, the practical question is whether to commit fresh capital now or wait for a pullback. The valuation work comes next.

Teva Pharmaceutical Industries closed at $36.44 compared with a narrative fair value of $40.90. This frames the current discussion around what assumptions sit underneath that gap.

Want to understand why this fair value sits above today’s price? The narrative leans on future earnings power, richer margins and a premium profit multiple. The assumptions behind that mix might surprise you.

Have a read of the narrative in full and understand what’s behind the forecasts.

However, Teva Pharmaceutical Industries still faces concentration risk in a handful of branded drugs and a sizeable debt load that could constrain flexibility if conditions worsen.

Find out about the key risks to this Teva Pharmaceutical Industries narrative.

Another View: What Teva Pharmaceutical Industries’ P/E Is Telling You

The first fair value of $40.90 points to Teva Pharmaceutical Industries trading at a discount. The P/E picture looks very different. At about 60.1x, the current P/E is far above the US pharmaceuticals industry at 16.7x and the peer average at 19.3x. It is also well above a 34.1x fair ratio. That gap suggests investors risk overpaying if the optimistic earnings path or sentiment cools.…Read more by Simply Wall St